Skip to main content

Logo
  • Live News iconLive News
  • Smart Screener iconSmart Screener
  • Trade Opportunities iconTrade Opportunities
  • Alpha Watch iconAlpha Watch
  • Catalyst iconCatalyst
Skip to main content
Stock Ask Logo
Hi, Guest User

Log in or create an account to get full access

Open an Account (opens in a new window)

TOOLS

Live News
Smart Screener
Trade Opportunities
Alpha Watch
Catalyst

StockkASK powered by Indira Securities

Quest Laboratories Ltd (QUESTLAB) Share Price & Fundamentals

Company Overview

Founded Year

1998

Listed Year

2024

Headquarter

Pithampur, Dhar, Madhya Pradesh, India

MD/CEO

-

Website

https://www.questlabltd.com

Company Facts

What we do

Quest Laboratories Limited manufactures a wide range of pharmaceutical formulations, including antibiotics, respiratory, diabetic, and antidepressant medications, specializing in ethical, generic, and OTC drugs.

Founded in

1,998

Market share

Growing presence in the Indian pharmaceutical market with WHO GMP and GLP certifications, listed on NSE SME Emerge, demonstrating credible quality standards.

Problem solved

Providing affordable, high-quality pharmaceuticals to meet diverse healthcare needs and market demand, adapting product mix flexibly.

Top clients or who we serve

Serving healthcare providers, pharmacies, and end consumers in India; operates mainly B2B and B2C segments.

Key management

-

Our journey and innovations

Incorporated in 1998, transitioned to a public limited company in 2024, launched IPO raising Rs 43.16 crores, developed versatile manufacturing with 600+ formulation approvals.

Where we operate

Primarily India with certified manufacturing facility at Pithampur, Madhya Pradesh, serving domestic markets.

Top products or what we offer

Ethical drugs, generics, OTC formulations across various therapeutic areas including antibiotics, antimalarials, and diabetes treatments.

Top brands

-

Raw materials needed

Pharmaceutical raw chemicals and active pharmaceutical ingredients (APIs).

Raw materials supplier

-

Recurring vs cyclical contribution

Revenue mainly from cyclical sales aligned with pharmaceutical market demand and seasonal health trends.

Our industry position

A recognized small-mid scale pharmaceutical manufacturer certified for quality and compliance, growing revenue base.

Financial highlights

FY 2024-25 revenue Rs 103.97 crores (+30.7% YoY), net profit Rs 13.57 crores (+34% YoY), EPS Rs 8.28 per share.

Geographical revenue split

Revenue predominantly from Indian markets; no detailed regional split disclosed.

Order book

-

Whats driving growth

Increased turnover driven by market demand, product portfolio expansion, and IPO fund infusion.

Our future plans

Focus on scaling production, launching new formulations, and leveraging flexible manufacturing for market responsiveness.

Our green promise

Committed to water conservation through rainwater harvesting and sustainable natural resource use.

Our people and values

Culturally diverse workforce with nondiscriminatory hiring, emphasis on training and social inclusion.

Key challenges ahead

Managing competitive pressures, regulatory compliance, and scaling production while maintaining quality.

Interesting facts

Holds over 600 formulation approvals, flexible manufacturing adapts product mix quickly per market needs.

Risks and strategy

Risks include market competition and regulatory changes; mitigated through quality certifications and diversified product lines.

Market Footprint

Top Clients

Top Clients

Serving healthcare providers, pharmacies, and end consumers in India; operates mainly B2B and B2C segments.

Top Products

Top Products

Ethical drugs, generics, OTC formulations across various therapeutic areas including antibiotics, antimalarials, and diabetes treatments.

Price Movement & Share Holding

Today's High/Low

80.183.9

52 Week High/Low

68.6160
Past Returns

1 week

-2.86%

1 month

-4.61%

3 month

-10.63%

1 year

-4.87%

3 year

-42.38%

5 year

-42.38%

Share Holding

Promoters

66.78%

FII

0.66%

DII

1.9%

Retail

29.43%

Others

1.23%

Company Overview

Founded Year

1998

Listed Year

2024

Headquarter

Pithampur, Dhar, Madhya Pradesh, India

MD/CEO

-

Website

https://www.questlabltd.com

Price Movement & Share Holding

Today's High/Low

80.183.9

52 Week High/Low

68.6160

Past Returns

1 week

-2.86%

1 month

-4.61%

3 month

-10.63%

1 year

-4.87%

3 year

-42.38%

5 year

-42.38%

Share Holding

Promoters

66.78%

FII

0.66%

DII

1.9%

Retail

29.43%

Others

1.23%

Company Facts

What we do

Quest Laboratories Limited manufactures a wide range of pharmaceutical formulations, including antibiotics, respiratory, diabetic, and antidepressant medications, specializing in ethical, generic, and OTC drugs.

Founded in

1998

Market share

Growing presence in the Indian pharmaceutical market with WHO GMP and GLP certifications, listed on NSE SME Emerge, demonstrating credible quality standards.

Problem solved

Providing affordable, high-quality pharmaceuticals to meet diverse healthcare needs and market demand, adapting product mix flexibly.

Top clients or who we serve

Serving healthcare providers, pharmacies, and end consumers in India; operates mainly B2B and B2C segments.

Our journey and innovations

Incorporated in 1998, transitioned to a public limited company in 2024, launched IPO raising Rs 43.16 crores, developed versatile manufacturing with 600+ formulation approvals.

Where we operate

Primarily India with certified manufacturing facility at Pithampur, Madhya Pradesh, serving domestic markets.

Top products or what we offer

Ethical drugs, generics, OTC formulations across various therapeutic areas including antibiotics, antimalarials, and diabetes treatments.

Raw materials needed

Pharmaceutical raw chemicals and active pharmaceutical ingredients (APIs).

Recurring vs cyclical contribution

Revenue mainly from cyclical sales aligned with pharmaceutical market demand and seasonal health trends.

Our industry position

A recognized small-mid scale pharmaceutical manufacturer certified for quality and compliance, growing revenue base.

Financial highlights

FY 2024-25 revenue Rs 103.97 crores (+30.7% YoY), net profit Rs 13.57 crores (+34% YoY), EPS Rs 8.28 per share.

Geographical revenue split

Revenue predominantly from Indian markets; no detailed regional split disclosed.

Whats driving growth

Increased turnover driven by market demand, product portfolio expansion, and IPO fund infusion.

Our future plans

Focus on scaling production, launching new formulations, and leveraging flexible manufacturing for market responsiveness.

Our green promise

Committed to water conservation through rainwater harvesting and sustainable natural resource use.

Our people and values

Culturally diverse workforce with nondiscriminatory hiring, emphasis on training and social inclusion.

Key challenges ahead

Managing competitive pressures, regulatory compliance, and scaling production while maintaining quality.

Interesting facts

Holds over 600 formulation approvals, flexible manufacturing adapts product mix quickly per market needs.

Risks and strategy

Risks include market competition and regulatory changes; mitigated through quality certifications and diversified product lines.

Market Footprint

Top Clients

Top Clients

Serving healthcare providers, pharmacies, and end consumers in India; operates mainly B2B and B2C segments.

Top Products

Top Products

Ethical drugs, generics, OTC formulations across various therapeutic areas including antibiotics, antimalarials, and diabetes treatments.

StockkASK provides smart, AI-powered insights to support analysis. AI can make mistakes; verify independently before investing.Terms & Conditions